LT5069B - Priešvėžinio vaisto stabili farmacinė forma ir jos gamybos būdas - Google Patents
Priešvėžinio vaisto stabili farmacinė forma ir jos gamybos būdas Download PDFInfo
- Publication number
- LT5069B LT5069B LT2003031A LT2003031A LT5069B LT 5069 B LT5069 B LT 5069B LT 2003031 A LT2003031 A LT 2003031A LT 2003031 A LT2003031 A LT 2003031A LT 5069 B LT5069 B LT 5069B
- Authority
- LT
- Lithuania
- Prior art keywords
- solvents
- paclitaxel
- water
- pharmaceutical form
- mixture
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 28
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 28
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 28
- 239000002904 solvent Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000000859 sublimation Methods 0.000 claims abstract description 10
- 230000008022 sublimation Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 3
- 230000007935 neutral effect Effects 0.000 claims abstract description 3
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract 6
- 230000036512 infertility Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract description 2
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 238000001035 drying Methods 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000003978 infusion fluid Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004809 Teflon Substances 0.000 description 4
- 229920006362 Teflon® Polymers 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CPHHUZWBNPKJIN-UHFFFAOYSA-N acetonitrile;1,4-dioxane;ethanol Chemical compound CCO.CC#N.C1COCCO1 CPHHUZWBNPKJIN-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL343615A PL203300B1 (pl) | 2000-10-31 | 2000-10-31 | Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2003031A LT2003031A (en) | 2003-09-25 |
| LT5069B true LT5069B (lt) | 2003-11-25 |
Family
ID=20077651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2003031A LT5069B (lt) | 2000-10-31 | 2003-05-05 | Priešvėžinio vaisto stabili farmacinė forma ir jos gamybos būdas |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1363892B1 (cs) |
| AU (1) | AU2002212863A1 (cs) |
| BG (1) | BG65985B1 (cs) |
| CZ (1) | CZ300836B6 (cs) |
| DE (1) | DE60122384T2 (cs) |
| HU (1) | HUP0303089A3 (cs) |
| LT (1) | LT5069B (cs) |
| PL (1) | PL203300B1 (cs) |
| RU (1) | RU2236227C1 (cs) |
| SI (1) | SI21138B (cs) |
| SK (1) | SK287850B6 (cs) |
| UA (1) | UA75620C2 (cs) |
| WO (1) | WO2002036582A1 (cs) |
| ZA (1) | ZA200303276B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005038A (es) * | 2001-11-30 | 2004-08-11 | Bristol Myers Squibb Co | Solvatos de paclitaxel. |
| DK1694660T3 (da) | 2003-12-12 | 2009-08-10 | Biorganica Ltda | Fremgangsmåde til fremstilling af vandfri og hydrerede aktive farmaceutiske bestanddele (API's); stabile farmaceutiske sammensætninger fremstillet af disse og anvendelser af disse sammensætninger |
| AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| EP2146695A4 (en) * | 2007-04-23 | 2010-05-19 | Sun Pharmaceuticals Ind Ltd | PHARMACEUTICAL COMPOSITIONS |
| RU2370258C2 (ru) * | 2007-11-16 | 2009-10-20 | Закрытое Акционерное Общество "Биокад" | Фармацевтическая композиция для парентеральной доставки в форме лиофилизата и способ ее получения |
| CN110437179A (zh) * | 2019-08-22 | 2019-11-12 | 江苏红豆杉药业有限公司 | 一种紫杉醇单晶晶体及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL169372B1 (en) | 1991-07-08 | 1996-07-31 | Rhone Poulenc Rorer Sa | Method of obtaining a pharmaceutical composition containing novel derivative of taxames group |
| PL176826B1 (pl) | 1993-09-29 | 1999-07-30 | Bristol Myers Squibb Co | Stabilizowana kompozycja przeciwnowotworowa i sposób wytwarzania stabilizowanej kompozycji przeciwnowotworowej |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2136673C1 (ru) * | 1992-12-24 | 1999-09-10 | Бристоль-Мейерз Сквибб Компани | Фосфонооксиметиловые эфиры таксановых производных, промежуточные соединения, противоопухолевая фармацевтическая композиция, способ ингибирования роста опухоли у млекопитающих |
| CA2163837C (en) * | 1994-12-13 | 1999-07-20 | Robert K. Perrone | Crystalline paclitaxel hydrates |
| FR2729666A1 (fr) * | 1995-01-25 | 1996-07-26 | Rhone Poulenc Rorer Sa | Procede de preparation du trihydrate du (2r, 3s)- benzoylamino-2-hydroxy-3-phenylpropionate de 4,10-diacetoxy- 2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxo- tax-11-en-13alpha-yle |
| FR2740686B1 (fr) * | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
-
2000
- 2000-10-31 PL PL343615A patent/PL203300B1/pl not_active IP Right Cessation
-
2001
- 2001-10-19 EP EP01981204A patent/EP1363892B1/en not_active Expired - Lifetime
- 2001-10-19 RU RU2003116136/15A patent/RU2236227C1/ru not_active IP Right Cessation
- 2001-10-19 WO PCT/PL2001/000082 patent/WO2002036582A1/en not_active Ceased
- 2001-10-19 CZ CZ20031421A patent/CZ300836B6/cs not_active IP Right Cessation
- 2001-10-19 HU HU0303089A patent/HUP0303089A3/hu unknown
- 2001-10-19 DE DE60122384T patent/DE60122384T2/de not_active Expired - Lifetime
- 2001-10-19 UA UA2003055025A patent/UA75620C2/uk unknown
- 2001-10-19 SK SK629-2003A patent/SK287850B6/sk not_active IP Right Cessation
- 2001-10-19 SI SI200120060A patent/SI21138B/sl not_active IP Right Cessation
- 2001-10-19 AU AU2002212863A patent/AU2002212863A1/en not_active Abandoned
-
2003
- 2003-04-25 BG BG107764A patent/BG65985B1/bg unknown
- 2003-04-29 ZA ZA200303276A patent/ZA200303276B/xx unknown
- 2003-05-05 LT LT2003031A patent/LT5069B/lt not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL169372B1 (en) | 1991-07-08 | 1996-07-31 | Rhone Poulenc Rorer Sa | Method of obtaining a pharmaceutical composition containing novel derivative of taxames group |
| PL176826B1 (pl) | 1993-09-29 | 1999-07-30 | Bristol Myers Squibb Co | Stabilizowana kompozycja przeciwnowotworowa i sposób wytwarzania stabilizowanej kompozycji przeciwnowotworowej |
Non-Patent Citations (2)
| Title |
|---|
| ROWINSKY EK, CAZENAVE LA, DONEHOWER RC.: "Taxol: a novel investigational antimicrotubule agent", J NATL CANCER INST., 1990, pages 1247 - 1259, XP002054343, DOI: doi:10.1093/jnci/82.15.1247 |
| SLICHENMYER WJ, VON HOFF DD.: "New natural products in cancer chemotherapy", J. CLIN. PHARMACOL., 1990, pages 770 - 788 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60122384D1 (de) | 2006-09-28 |
| AU2002212863A1 (en) | 2002-05-15 |
| HK1060733A1 (en) | 2004-08-20 |
| DE60122384T2 (de) | 2007-08-16 |
| WO2002036582A1 (en) | 2002-05-10 |
| LT2003031A (en) | 2003-09-25 |
| SI21138B (sl) | 2006-10-31 |
| SI21138A (sl) | 2003-08-31 |
| CZ20031421A3 (cs) | 2004-06-16 |
| HUP0303089A3 (en) | 2005-02-28 |
| SK287850B6 (sk) | 2012-01-04 |
| BG65985B1 (bg) | 2010-08-31 |
| EP1363892B1 (en) | 2006-08-16 |
| ZA200303276B (en) | 2004-04-21 |
| UA75620C2 (en) | 2006-05-15 |
| RU2236227C1 (ru) | 2004-09-20 |
| HUP0303089A2 (hu) | 2003-12-29 |
| EP1363892A1 (en) | 2003-11-26 |
| BG107764A (bg) | 2004-07-30 |
| CZ300836B6 (cs) | 2009-08-19 |
| PL203300B1 (pl) | 2009-09-30 |
| SK6292003A3 (en) | 2004-08-03 |
| PL343615A1 (en) | 2002-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2144356C1 (ru) | Композиция для инъекций на основе таксоидов | |
| CN1112924C (zh) | 用于静脉注射的雷怕霉素制剂 | |
| RU2429837C2 (ru) | Фармацевтический состав таксана, твердая композиция таксана, способ получения твердой композиции таксана, композиция для солюбилизации указанной твердой композиции таксана и комплект элементов (набор) для состава таксана для инъекций | |
| SK287487B6 (sk) | Lyofilizovaná kompozícia a rekonštituovaná lyofilizovaná kompozícia | |
| HU217839B (hu) | Eljárások taxánszármazékokat tartalmazó új stabil gyógyszerkészítmények előállítására | |
| KR20100023862A (ko) | 트윈 80을 함유하지 않은 도세탁셀의 용해 제제 | |
| KR20140067034A (ko) | 카바지탁셀 제제와 이를 제조하는 방법 | |
| EA002776B1 (ru) | Фармацевтические композиции, содержащие циклодекстрины и таксоиды | |
| KR100785603B1 (ko) | 치환된 벤즈이미다졸의 제제 | |
| CZ298581B6 (cs) | Farmaceuticky stabilní prípravek oxaliplatiny k parenterální aplikaci | |
| EA016619B1 (ru) | Новые композиции на основе таксоидов | |
| BR112021011495A2 (pt) | Preparação incluindo adjuvante para vacina | |
| LT5069B (lt) | Priešvėžinio vaisto stabili farmacinė forma ir jos gamybos būdas | |
| JP2011529930A (ja) | 注射可能タキサン医薬品組成物 | |
| JP3584064B2 (ja) | 静脈注射用ラパマイシン製剤 | |
| WO2024095053A1 (en) | Novel non-oral formulations of factor xa inhibitors and process for preparation thereof | |
| WO2024224308A1 (en) | Liquid parenteral formulations of bilastine free of cyclodextrins | |
| WO2024127418A1 (en) | Injectable compositions of posaconazole | |
| WO2024224424A1 (en) | Injectable compositions of metolazone | |
| WO2025206172A1 (ja) | 電子線滅菌処理したヘテロシクリデンアセトアミド誘導体含有組成物 | |
| WO2024075135A1 (en) | "stable injectable compositions of glp-2 peptide" | |
| HK1060733B (en) | Method for the production of a stable pharmaceutical form of paclitaxel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20121019 |